218 related articles for article (PubMed ID: 23372824)
21. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
van den Berg-Wolf M; Hullsiek KH; Peng G; Kozal MJ; Novak RM; Chen L; Crane LR; Macarthur RD;
HIV Clin Trials; 2008; 9(5):324-36. PubMed ID: 18977721
[TBL] [Abstract][Full Text] [Related]
22. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
23. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Chetty T; Thorne C; Coutsoudis A
PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
[TBL] [Abstract][Full Text] [Related]
24. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
[TBL] [Abstract][Full Text] [Related]
25. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial.
Wester CW; Stitelman OM; deGruttola V; Bussmann H; Marlink RG; van der Laan MJ
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):981-8. PubMed ID: 22309114
[TBL] [Abstract][Full Text] [Related]
26. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Bartelink IH; Savic RM; Dorsey G; Ruel T; Gingrich D; Scherpbier HJ; Capparelli E; Jullien V; Young SL; Achan J; Plenty A; Charlebois E; Kamya M; Havlir D; Aweeka F
Pediatr Infect Dis J; 2015 Mar; 34(3):e63-70. PubMed ID: 25742090
[TBL] [Abstract][Full Text] [Related]
27. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
[TBL] [Abstract][Full Text] [Related]
28. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
29. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
30. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
[TBL] [Abstract][Full Text] [Related]
32. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
33. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
[TBL] [Abstract][Full Text] [Related]
34. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
[TBL] [Abstract][Full Text] [Related]
36. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
37. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
38. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
40. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
